Sanifit logo portada

A new approach to
calcification disorders

Sanifit logo portada

A new approach to
calcification disorders

sanifit

SANIFIT

Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA.

Sanifit’s lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite (HAP) crystallisation, the final common pathway that leads to vascular calcification. SNF472 is in clinical development for the treatment of calciphylaxis or CUA (calcific uremic arteriolopathy) in patients undergoing dialysis. In 2018 Sanifit completed a Phase 2 proof-of-concept trial in patients with calciphylaxis, which met its primary and secondary endpoints. A Phase 3 pivotal study in calciphylaxis is in preparation. The company is also investigating SNF472 in a Phase 2b study (CaLIPSO) to assess its effect on slowing arterial calcification, a major risk factor for cardiovascular disease (CVD) in patients on dialysis. Results from this study on the effect of SNF472 on calcification in coronary arteries, aorta and heart valves are expected in Q4 2019

 

ABOUT US

PROJECT SUPPORTED BY

Número de proyecto: RTC-2014-2460-1
Título: RETOS COLABORACION
Nombre del Ministerio: Ministerio de Ciencia, Innovación y Universidades

LATEST NEWS

Your name (required)

Phone (required)

Company

E-mail (required)

Comments


[recaptcha id:sani-captcha class:sani-captcha]

CONTACT

Sanifit


SPAIN
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma

 

 +34 971 439 925
 info@sanifit.com

USA
3655 Nobel Drive
Suite #540
San Diego, CA 92122